Opus Genetics Inc. Common Stock (IRD)
Stock · NASDAQ · Health Care
$3.85as of 10/16/2026
Price chart
Active signals
IRD Signal Track Record
How signals performed across all stocks →What IRD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +1.8% | 51% | August 25, 2026 |
| Bollinger Band Breakout | 23 | -3.8% | 39% | September 2, 2026 |
| Bollinger Band BreakdownActive now | 22 | +5.5% | 68% | July 14, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +17.3% | 67% | August 31, 2026 |
| Any 20-session window (baseline) | +0.5% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associa…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 27
- Website
- opusgtx.com/
Fundamentals
- 1-day range
- $3.76$4.12
- Market cap
- $307.14M
- P/E (trailing)
- —
- P/E (forward)
- -5.45
- EPS (trailing)
- $-1.29
- Dividend yield
- —
- Beta
- 0.77
- Avg. volume
- 2.44M
- Dividend pay date
- November 6, 2020
How Opus Genetics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
17 analyst ratings
Opus Genetics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IRDOpus Genetics Inc. Common Stock$3.84▼ 5.19%Market cap $307.14MP/E —$1.7$7.07
- VNDAVanda Pharmaceuticals Inc. Common Stock$4.03▼ 4.95%Market cap $307.59MP/E —$4.27$9.94
- ORGOOrganogenesis Holdings Inc. Class A Common Stock$1▼ 9.91%Market cap $310.11MP/E 84.95$1.13$7.08
- AMRNAmarin Corporation plc$11.32▼ 2.16%Market cap $301.21MP/E —$11.34$20.9
- GALTGalectin Therapeutics Inc. Common Stock$3.62▼ 2.43%Market cap $324.74MP/E —$2.03$7.13
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
- FULCFulcrum Therapeutics Inc. Common Stock$3.65▼ 0.54%Market cap $287.64MP/E —$2.83$15.74
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IRD Opus Genetics Inc. Common Stock | $307.14M | — | $3.84 | ▼ 5.19% | $1.7$7.07 |
| VNDA Vanda Pharmaceuticals Inc. Common Stock | $307.59M | — | $4.03 | ▼ 4.95% | $4.27$9.94 |
| ORGO Organogenesis Holdings Inc. Class A Common Stock | $310.11M | 84.95 | $1 | ▼ 9.91% | $1.13$7.08 |
| AMRN Amarin Corporation plc | $301.21M | — | $11.32 | ▼ 2.16% | $11.34$20.9 |
| GALT Galectin Therapeutics Inc. Common Stock | $324.74M | — | $3.62 | ▼ 2.43% | $2.03$7.13 |
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
| FULC Fulcrum Therapeutics Inc. Common Stock | $287.64M | — | $3.65 | ▼ 0.54% | $2.83$15.74 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- George Magrath · July 23, 2026 · Sale9.5K @ $2.95
- Robert E. Gagnon · July 23, 2026 · Sale7.8K @ $2.95
- Joseph K. Schachle · July 23, 2026 · Sale4.6K @ $2.94
- Benjamin R. Yerxa · July 23, 2026 · Sale7.4K @ $2.97
- Foundation Fighting Blindness Retinal Degeneration Fund · May 18, 2026 · Sale1.70M @ $4.35
- Rabourn Amy Zaremba · April 23, 2026 · Sale1.6K @ $5.2
- George Magrath · April 23, 2026 · Sale9.5K @ $5.22
- Ashwath Jayagopal · April 23, 2026 · Sale7.5K @ $5.19
- Robert E. Gagnon · April 23, 2026 · Sale7.8K @ $5.18
- Joseph K. Schachle · April 23, 2026 · Sale4.7K @ $5.22
- Benjamin R. Yerxa · April 23, 2026 · Sale7.5K @ $5.24
- Richard J. Rodgers · April 20, 2026 · Grant24.4K
- James S. J. Manuso · April 20, 2026 · Grant24.4K
- Adrienne L. Graves · April 20, 2026 · Grant24.4K
- Cam Gallagher · April 20, 2026 · Grant24.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 45.23M
- Total value held
- $202.56M
- Institutional holders
- 77
- Unknown6.08M
- Unknown6.03M
- Unknown3.68M
- Unknown2.72M
- Unknown2.63M
- Unknown2.45M
- Unknown2.31M
- Unknown2.25M
- Unknown1.85M
- Unknown1.84M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Opus Genetics to Present at Euretina 2026
Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.
Opus Genetics to Present at Euretina 2026. Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.